Quince Therapeutics is a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform the lives of patients suffering from debilitating and rare diseases. Quince is in the process of closing the acquisition of EryDel SpA and its Phase 3 clinical asset EryDex that targets a rare fatal pediatric neurological disease called Ataxia-Telangiectasia (A-T) – which currently has no approved treatments and represents an estimated $1+ billion peak sales opportunity.
